Table 1.

Selected characteristics by p53 and MAPK expression in invasive ovarian tumors in the NHS, NHS II, and NECC

Controls (n = 1,907)p53 wild-type (n = 88)p53 mutanta (n = 186)MAPK (n = 142)MAPK+a (n = 132)
Mean (SD)
 Age at diagnosis57.2 (11.2)58.2 (9.5)60.9 (9.9)59.3 (9.7)60.8 (10.0)
N (%)
Study
 NHS866 (45.4)56 (63.6)114 (61.3)89 (62.7)81 (61.4)
 NHS II184 (9.6)14 (15.9)18 (9.7)16 (11.3)16 (12.1)
 NECC857 (44.9)18 (20.5)54 (29.0)37 (26.1)35 (26.5)
Family history of breast or ovarian cancer306 (16.0)16 (18.2)39 (21.0)39 (27.5)16 (12.1)
Age at menarche
 <13 years927 (48.6)39 (44.3)86 (46.2)67 (47.2)58 (43.9)
 13+ years979 (51.4)49 (55.7)100 (53.8)75 (52.8)74 (56.1)
Oral contraceptive use
 Never762 (40.3)39 (45.3)97 (52.4)69 (48.9)67 (51.5)
 <1 year205 (10.8)11 (12.8)24 (13.0)16 (11.3)19 (14.6)
 1–4 years421 (22.3)23 (26.7)41 (22.2)39 (27.7)25 (19.2)
 5–9 years280 (14.8)10 (11.6)17 (9.2)11 (7.8)16 (12.3)
 10+ years222 (11.7)3 (3.5)6 (3.2)6 (4.3)3 (2.3)
Tubal ligation404 (21.2)10 (11.4)19 (10.2)19 (13.4)10 (7.6)
Parity
 Nulliparous207 (10.9)19 (21.8)17 (9.1)21 (14.8)15 (11.5)
 1–2 children812 (42.6)38 (43.7)81 (43.5)67 (47.2)52 (39.7)
 3–4 children716 (37.6)20 (23.0)63 (33.9)37 (26.1)46 (35.1)
 5+ children171 (9.0)10 (11.5)25 (13.4)17 (12.0)18 (13.7)
Menopausal status
 Premenopausal/Unknown626 (32.8)24 (27.3)39 (21.0)40 (28.2)23 (17.4)
 Postmenopausal1,281 (67.2)64 (72.7)147 (79.0)102 (71.8)109 (82.6)
Age at menopauseb
 <50413 (36.9)24 (46.2)37 (34.3)30 (40.5)31 (36.0)
 50+707 (63.1)28 (53.8)71 (65.7)44 (59.5)55 (64.0)
Ever hormone therapy (HT) useb551 (46.3)35 (58.3)71 (57.3)48 (53.3)58 (61.7)
 Ever estrogen only237 (19.9)20 (33.3)44 (35.5)31 (34.4)33 (35.1)
 Ever estrogen and progesterone340 (28.6)19 (31.7)35 (28.2)20 (22.2)34 (36.2)
 Ever other HT121 (10.2)7 (11.7)11 (8.9)11 (12.2)7 (7.4)
Histology and grade
 Serous, low grade4 (4.6)4 (2.2)4 (2.8)4 (3.0)
 Serous, high grade35 (39.8)133 (71.5)80 (56.3)88 (66.7)
 Endometrioid, low grade11 (12.5)5 (2.7)13 (9.2)3 (2.3)
 Endometrioid, high grade15 (17.1)18 (9.7)14 (9.9)19 (14.4)
 Mucinous1 (1.1)3 (1.6)3 (2.1)1 (0.8)
 Clear cell18 (20.5)6 (3.2)14 (9.9)10 (7.6)
 Other4 (4.6)17 (9.1)14 (9.9)7 (5.3)
MAPK positive34 (38.6)98 (52.7)
p53 mutant88 (62.0)98 (74.2)
  • NOTE: Missing (age at menarche N = 1, OC use N = 20, parity N = 2, age at natural menopause among postmenopausal women N = 212, HT use among postmenopausal women N = 118).

  • aMutant p53 defined as 0% of cells stained positive or >50% stained positive. MAPK was considered positive if >10% of cells stained positive.

  • bAmong postmenopausal women.